Functional mushroom supplements have grown considerably in popularity, and many people take them alongside prescription medications without disclosing this to their healthcare providers. While most mushroom extracts have favorable safety profiles in clinical research, the assumption that natural products are universally safe warrants scrutiny. Several mechanisms through which commonly used mushroom supplements may interact with pharmaceuticals have been identified in the published literature. This article reviews the current evidence on these interactions to help consumers and clinicians make better-informed decisions.
Why Drug Interactions Matter With Mushroom Supplements
Natural products can interact with pharmaceutical drugs through two broad pathways. The first is pharmacodynamic: the supplement and the drug produce overlapping or opposing effects on the same physiological system. The second is pharmacokinetic: the supplement alters the absorption, distribution, metabolism, or excretion of the drug, typically by influencing cytochrome P450 (CYP) enzyme activity in the liver or intestinal lining.
Functional mushrooms are primarily composed of beta-glucan polysaccharides, triterpenoids, and phenolic compounds. These constituents are largely metabolized through pathways distinct from most pharmaceuticals, but several specific concerns have been identified. A 2025 scoping review published in Pharmaceuticals (Basel) analyzed safety data from 285 clinical trials and 119 case studies involving adaptogenic and immunomodulatory natural products, including mushroom-derived preparations. The authors reported that adverse events, including hepatic, cardiovascular, and immunological reactions, were documented, and noted that for Ganoderma lucidum specifically, the pharmacovigilance database VigiBase contained a meaningful number of serious adverse event reports. The review emphasized that variability in product composition and incomplete reporting in clinical studies complicate accurate risk assessment.[1]
Anticoagulant and Antiplatelet Medications
Among the most clinically significant potential interactions involves mushroom supplements and anticoagulant or antiplatelet drugs such as warfarin, aspirin, clopidogrel, or newer anticoagulants like apixaban and rivaroxaban.
An in vitro screening study published in Nutrients (2019) evaluated the antiplatelet and anticoagulant activity of hot water extracts from eight commonly consumed mushroom species. The study found that Ganoderma lucidum (reishi) extract demonstrated inhibition of both ADP-induced and arachidonic acid-induced platelet aggregation in human blood samples. The effect on ADP-induced aggregation exceeded that of 140 micromoles per liter of acetylsalicylic acid (aspirin) in the in vitro model. Notably, the reishi extract also showed cytotoxic effects on platelets and leukocytes at the tested concentrations. Other species, including Pleurotus ostreatus (oyster mushroom), showed an additive effect on arachidonic acid-induced aggregation, suggesting the relevant activity is not limited to reishi.[2]
These in vitro findings do not directly predict in vivo outcomes in humans, and no controlled clinical trials have measured INR or bleeding outcomes in patients taking standard anticoagulants alongside mushroom supplements. However, the mechanistic basis for a potential additive interaction is established. Individuals taking blood-thinning medications should discuss any mushroom supplement use with a prescriber before beginning.
Immunosuppressant Medications
Several functional mushrooms are studied specifically for their immunomodulatory properties. Reishi, turkey tail, and lion’s mane all show evidence of influencing immune cell activity, including T-cell and natural killer cell function. This creates a theoretically relevant concern for people taking immunosuppressant medications following organ transplantation or for the management of autoimmune conditions such as rheumatoid arthritis, lupus, or inflammatory bowel disease.
If a mushroom supplement stimulates immune cell activity through pathways that overlap with those targeted by an immunosuppressant, it may counteract the intended effect of the medication. While this theoretical interaction has not been definitively studied in controlled human trials, immunologists and transplant pharmacists generally advise caution. The same scoping review noted that immunological reactions were among the documented adverse event categories for adaptogenic and immunomodulatory natural products, reinforcing the importance of provider disclosure for this population.[1]
Chemotherapy and Oncology Medications
A case report published in the Journal of Oncology Pharmacy Practice (2025) describes a 43-year-old woman with metastatic colorectal cancer who developed grade 3 cytolysis and hepatic cholestasis while undergoing chemotherapy. Investigation revealed she had been taking a dietary supplement containing Agaricus blazei Murrill (ABM) and Hericium erinaceus (lion’s mane) powder for several months. Chemotherapy was canceled, the supplement was discontinued, and liver function markers normalized. Given that the patient’s baseline liver values had been normal, the authors concluded that hepatic cytolysis appeared to be linked to the mushroom supplement, noting that the patient’s existing liver metastases made definitive attribution difficult. They called for pharmaceutical review of complementary and alternative medicine use in all oncology patients.[3]
This case illustrates several important realities: first, that mushroom supplement-related adverse effects can be clinically significant in vulnerable populations; second, that patients frequently do not disclose supplement use to oncology teams; and third, that effects may be compounded when organ function is already compromised by disease or treatment.
Turkey Tail’s PSK and Chemotherapy Context
It is worth distinguishing the above safety concern from the context in which turkey tail’s polysaccharide-K (PSK) has been studied. PSK has been investigated as an adjunct therapy in oncology settings in Japan, where it is used under medical supervision to support immune function during conventional cancer treatment. This represents a different scenario from self-administered dietary supplements taken without medical oversight, and the PSK clinical literature is not an endorsement of unmonitored mushroom supplement use during chemotherapy.
Blood Glucose-Lowering Medications
Certain functional mushrooms, particularly maitake (Grifola frondosa) and reishi, have been studied in the context of blood glucose modulation. Maitake’s SX-fraction and related polysaccharides have demonstrated hypoglycemic effects in animal models and some small human studies. If these effects occur in individuals already taking metformin, insulin, or other glucose-lowering agents, there is a theoretical risk of additive blood glucose reduction.
This does not mean people with diabetes should avoid functional mushrooms, but it does indicate that blood glucose monitoring may be warranted when beginning supplementation, and that medication adjustments should be made only in consultation with a prescriber.
Hepatic Metabolism and Liver-Processed Medications
Some bioactive compounds in mushroom extracts have been investigated for potential effects on CYP enzyme activity, which influences how the liver processes a wide range of drugs. Triterpenoids from reishi, in particular, have been studied in vitro for CYP450 interactions. While the clinical significance of these findings in humans at typical supplemental levels remains unclear, individuals taking medications with narrow therapeutic windows, such as certain antiepileptics, statins, or immunosuppressants, should be aware that this mechanism may be relevant.
Chaga (Inonotus obliquus) presents an additional consideration: it contains relatively high levels of oxalates and has been associated with oxalate nephropathy in cases of prolonged, high-quantity consumption. In individuals with kidney impairment, this could indirectly affect the clearance of renally excreted medications.
Practical Guidance: Who Should Take Extra Precautions
Based on the available evidence, the following groups have the most clinically meaningful reasons to consult a healthcare provider before starting any mushroom supplement:
- Anyone taking anticoagulant or antiplatelet medications (warfarin, clopidogrel, aspirin at therapeutic doses, novel oral anticoagulants)
- Transplant recipients or anyone on immunosuppressants (tacrolimus, cyclosporine, mycophenolate)
- Individuals undergoing active cancer treatment, including chemotherapy, targeted therapy, or immunotherapy
- People managing diabetes with prescription medications, particularly insulin or sulfonylureas
- Those with chronic liver or kidney disease, which may affect how both supplements and medications are processed
- Individuals taking narrow therapeutic window drugs, such as certain antiepileptics or cardiac glycosides
Quality Variability Compounds the Challenge
A factor that makes assessing drug interaction risk more complicated is the significant variability in mushroom supplement quality and composition. Products differ in extraction method, active compound concentration, and the presence or absence of contaminants. A supplement that lists “reishi extract” on its label may contain vastly different quantities of the triterpenoids or polysaccharides with known pharmacological activity depending on whether it uses fruiting body or mycelium, hot water or dual extraction, and whether it has been tested for compound content. For a detailed look at how to evaluate supplement labeling, see our guide to How to Read a Mushroom Supplement Label: Beta-Glucans, Polysaccharides Explained.
Summary
Research suggests that functional mushroom supplements may interact with anticoagulants, immunosuppressants, glucose-lowering agents, and chemotherapy agents through both pharmacodynamic and pharmacokinetic mechanisms. While the evidence base for specific interactions in humans remains limited, case reports and pharmacovigilance data indicate that clinically significant adverse events can occur, particularly in vulnerable populations. Transparency with healthcare providers about supplement use is the most important practical step any consumer can take, particularly those managing chronic conditions with prescription medications.
References
- 1. Liang CJW, et al. Safety Considerations for Natural Products with Adaptogenic and Immunomodulating Activities. Pharmaceuticals (Basel). 2025;18(8):1208. PMID 40872598
- 2. Poniedziałek B, et al. The Effect of Mushroom Extracts on Human Platelet and Blood Coagulation: In vitro Screening of Eight Edible Species. Nutrients. 2019;11(12):3040. PMID 31842490
- 3. Strobbe G, et al. Grade 3 cytolysis in a patient with metastatic colorectal cancer consuming a mushroom powder-based alternative therapy. J Oncol Pharm Pract. 2025;31(2):329-335. PMID 39223928
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Functional mushroom supplements are not approved by the FDA to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare provider before adding any supplement to your routine, particularly if you have existing health conditions or take prescription medications.
